LakeShore Biopharma Co Ltd, formerly YS Biopharma Co Ltd, is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
äŒæ¥ã³ãŒãLSB
äŒç€ŸåLakeShore Biopharma Co Ltd
äžå Žæ¥Jul 30, 2021
æé«çµå¶è²¬ä»»è
ãCEOãMr. Dave Chenn
åŸæ¥å¡æ°573
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jul 30
æ¬ç€Ÿæåšå°Building No. 2, 38 Yongda Road
éœåžBEIJING
蚌åžååŒæNASDAQ Capital Market Consolidated
åœChina
éµäŸ¿çªå·102629
é»è©±çªå·
ãŠã§ããµã€ãhttps://www.ysbiopharm.com/
äŒæ¥ã³ãŒãLSB
äžå Žæ¥Jul 30, 2021
æé«çµå¶è²¬ä»»è
ãCEOãMr. Dave Chenn
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã